Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that correct RNA expression. Our founders are leading experts in small molecule therapeutics development for RNA-based disease. Our first drug candidates are targeted towards cancers and neurological conditions. The company is based in Waltham, Massachusetts. For more information, please visit: www.skyhawktx.com.
Location: United States, Massachusetts, Waltham
Employees: 51-200
Total raised: $48M
Founded date: 2016
Investors 4
| Date | Name | Website |
| - | Agent Capi... | agentcapit... |
| - | ShangPharm... | spiivc.com |
| - | Good Growt... | goodgrowth... |
| - | DNS Capita... | dnscap.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.06.2018 | - | $40M | - |
| 24.01.2018 | Seed | $8M | - |
Mentions in press and media 8
| Date | Title | Description |
| 22.04.2024 | Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases | Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development candidate validation, Ipsen will assume responsibility for further development and commercializ... |
| 28.02.2024 | Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease | SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform. Having successfully advanced through single asending dose, SKY-0515 is advancing into the Multiple Ascending Dose portion of its pha... |
| 23.10.2023 | Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington's Disease | SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform. SKY-0515's Phase 1 study will include healthy volunteers before targeting Huntington's patients. Huntington's disease is a fatal neu... |
| 23.01.2023 | Startups measuring the brain that you need to know | Companies are using biomarkers to diagnose and treat mental illness and other neurological disorders Mental illness is considered the silent pandemic that's been overlooked since the start of COVID. The World Health Organization found the g... |
| 26.06.2018 | Skyhawk Therapeutics Announces $40 Million Equity Investment Round | Skyhawk Therapeutics, Inc., today announced the closing of a new $40 million equity investment round alongside its recently announced $60 million strategic collaboration, bringing total new capital into the company to over $100 million. Pro... |
| 26.06.2018 | Skyhawk Therapeutics Raises $40M in Equity Funding Round | Skyhawk Therapeutics, Inc., a Cambridge, Mass.-based drug development company, closed a new $40m equity investment round alongside its recently announced $60m strategic collaboration. This brings total new capital into the company to over $... |
| 24.01.2018 | Skyhawk Therapeutics Raises $8M in Seed Financing | Skyhawk Therapeutics, Inc., a Waltham, Mass.-based company focused on the discovery and development of small molecule therapeutics that correct RNA expression, closed $8m seed funding round. The round was led by major family and biotech inv... |
| 23.01.2018 | Skyhawk Therapeutics Launches With $8 Million in Seed Financing | Skyhawk Therapeutics, Inc., a new private company focused on the discovery and development of small molecule therapeutics that correct RNA expression, today announced the close of $8 million in seed funding led by major family and biotech i... |